IL143313A0 - Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases - Google Patents
Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseasesInfo
- Publication number
- IL143313A0 IL143313A0 IL14331399A IL14331399A IL143313A0 IL 143313 A0 IL143313 A0 IL 143313A0 IL 14331399 A IL14331399 A IL 14331399A IL 14331399 A IL14331399 A IL 14331399A IL 143313 A0 IL143313 A0 IL 143313A0
- Authority
- IL
- Israel
- Prior art keywords
- disease
- alzheimer
- compositions
- methods
- nervous system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/200,700 US6191154B1 (en) | 1998-11-27 | 1998-11-27 | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
PCT/US1999/027987 WO2000032190A1 (en) | 1998-11-27 | 1999-11-24 | Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
IL143313A0 true IL143313A0 (en) | 2002-04-21 |
Family
ID=22742814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14331399A IL143313A0 (en) | 1998-11-27 | 1999-11-24 | Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases |
Country Status (10)
Country | Link |
---|---|
US (1) | US6191154B1 (xx) |
EP (1) | EP1133294B1 (xx) |
JP (4) | JP4932991B2 (xx) |
KR (2) | KR100520856B1 (xx) |
AT (1) | ATE478669T1 (xx) |
AU (1) | AU765528C (xx) |
CA (1) | CA2352494C (xx) |
DE (1) | DE69942702D1 (xx) |
IL (1) | IL143313A0 (xx) |
WO (1) | WO2000032190A1 (xx) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6521425B2 (en) * | 1997-03-05 | 2003-02-18 | New England Biolabs, Inc. | Screening and use of reagents which block or activate intein splicing utilizing natural or homologous exteins |
CA2220897A1 (en) | 1995-05-12 | 1996-11-14 | The Rockefeller University | Treatment of alzheimer disease by modulation of synapsins |
DE69838789T2 (de) * | 1997-03-12 | 2008-10-30 | Suzanne Cambridge de la Monte | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
US8518882B2 (en) * | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
US20050203053A1 (en) * | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
US8143234B2 (en) * | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
US8314064B2 (en) | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
CA2355645A1 (en) * | 1998-12-17 | 2000-06-22 | Mindset Biopharmaceuticals (Usa), Inc. | Increasing brain glucose utilization |
US20040034067A1 (en) * | 1999-04-15 | 2004-02-19 | Macphee Colin Houston | Novel method of treatment |
CA2371391A1 (en) * | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
GB9917405D0 (en) * | 1999-07-23 | 1999-09-22 | Univ Dundee | Methods of treatment and drug screening methods |
US20030195707A1 (en) * | 2000-05-25 | 2003-10-16 | Schork Nicholas J | Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof |
US20020077775A1 (en) * | 2000-05-25 | 2002-06-20 | Schork Nicholas J. | Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof |
GB0030845D0 (en) * | 2000-12-18 | 2001-01-31 | Smithkline Beecham Plc | Novel treatment |
US6613505B2 (en) | 2001-04-12 | 2003-09-02 | Bioresource International, Inc. | Composition and method for destruction of infetious prion proteins |
AU2002304931A1 (en) * | 2001-06-08 | 2002-12-23 | University Of British Columbia | Methods for treating disorders of the nervous and reproductive systems |
WO2002102364A1 (fr) * | 2001-06-18 | 2002-12-27 | Yamada, Sachiko | Preparations medicamenteuses agonistes ppar$g(g) |
IL160229A0 (en) * | 2001-08-10 | 2004-07-25 | Genset Sa | Polynucleotides, polypeptides encoded thereby and their use |
US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
FR2836829B1 (fr) * | 2002-03-11 | 2005-11-25 | Bio Merieux | Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro |
US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
EP1527781B1 (en) | 2002-08-09 | 2008-07-23 | Taisho Pharmaceutical Co., Ltd | Antipruritic agent |
US20050003998A1 (en) * | 2002-08-15 | 2005-01-06 | Goran Bertilsson | Therapeutic use of selective LXR modulators |
US20040122059A1 (en) * | 2002-10-01 | 2004-06-24 | The Penn State Research Foundation | PPAR-gamma ligands in the treatment of asthma and allergies |
US7981915B2 (en) | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
US20050107387A1 (en) * | 2003-05-13 | 2005-05-19 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders |
HU0301358D0 (en) | 2003-05-14 | 2003-07-28 | Debreceni Egyetem | Novel use of ppargamma agonists |
JP4556511B2 (ja) * | 2004-06-25 | 2010-10-06 | ソニー株式会社 | 15d−PGJ2、及び、15d−PGJ2を用いた方法 |
US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
US20090054523A1 (en) * | 2005-01-24 | 2009-02-26 | Morten Bryhn | Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases |
KR20130101596A (ko) * | 2005-07-08 | 2013-09-13 | 마텍 바이오싸이언스스 코포레이션 | 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산 |
KR20080058413A (ko) * | 2005-09-22 | 2008-06-25 | 에스비 팜코 푸에르토 리코 인크. | Apoe4 음성 환자에서의 인지 기능의 개선을 위한ppar-감마 작동제 |
US20100331330A1 (en) * | 2006-08-23 | 2010-12-30 | Landerth Gary E | Methods and compositions for treating ischemic stroke |
EP2044951A1 (en) | 2007-10-02 | 2009-04-08 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases |
US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
CN101896119A (zh) * | 2007-11-02 | 2010-11-24 | 麻省理工学院 | 尿苷饮食添加顺应性方法及其用途 |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
EP2324126B1 (en) | 2008-08-12 | 2014-04-23 | Zinfandel Pharmaceuticals, Inc. | METHOD OF IDENTIFYING Alzheimer's DISEASE RISK FACTORS |
US20120010264A1 (en) * | 2009-03-26 | 2012-01-12 | Dainippon Sumitomo Pharma Co., Ltd. | Novel medicament for treating cognitive impairment |
WO2011006157A2 (en) * | 2009-07-10 | 2011-01-13 | Case Western Reserve University | Rxr agonist compounds and methods |
WO2011047091A1 (en) * | 2009-10-13 | 2011-04-21 | Martek Biosciences Corporation | Methods for treating traumatic brain injury |
MX355479B (es) * | 2011-01-10 | 2018-04-19 | Zinfandel Pharmaceuticals Inc | Metodos y productos de farmaco para tratar enfermedad de alzheimer. |
WO2012100347A1 (en) * | 2011-01-24 | 2012-08-02 | Inceptum Research & Therapeutics, Inc. | Compositions comprising a prostaglandin for treating neuropsychiatric conditions |
KR20130015932A (ko) * | 2011-08-05 | 2013-02-14 | 연세대학교 산학협력단 | 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물 |
WO2013058409A1 (en) * | 2011-10-21 | 2013-04-25 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
JP2015505314A (ja) * | 2012-01-09 | 2015-02-19 | 武田薬品工業株式会社 | アルツハイマー病を治療する方法及び医薬品 |
US8865747B2 (en) | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
CN104341408A (zh) * | 2013-08-02 | 2015-02-11 | 江苏柯菲平医药股份有限公司 | 一种阿奇沙坦的新晶型及其制备方法 |
JP6163084B2 (ja) * | 2013-11-11 | 2017-07-12 | キリン株式会社 | 認知症の予防、治療及び/又は認知機能を改善する組成物、及びこれを用いた医薬、食品 |
EP3074525A4 (en) | 2013-11-26 | 2017-08-23 | University of North Texas Health Science Center at Fort Worth | Personalized medicine approach for treating cognitive loss |
US10188639B2 (en) * | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
DK3388064T3 (da) * | 2014-04-02 | 2021-04-19 | Minoryx Therapeutics S L | 2,4-thiazolidindionderivater i behandling af forstyrrelse i centralnervesystemet |
ES2867300T3 (es) | 2016-12-01 | 2021-10-20 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-diona para tratamiento de enfermedad de hígado graso no alcohólico |
GB201805554D0 (en) * | 2018-04-04 | 2018-05-16 | Wren Therapeutics | Therapy for protein misfolding disease |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
JPS58118577A (ja) | 1982-01-07 | 1983-07-14 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
HU210339B (en) | 1985-05-21 | 1995-03-28 | Pfizer | Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect |
US4873255A (en) | 1987-02-04 | 1989-10-10 | Sankyo Company Limited | Thiazolidinone derivatives, their preparation and their use |
FI91869C (fi) | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
EP0295828A1 (en) | 1987-06-13 | 1988-12-21 | Beecham Group Plc | Novel compounds |
US5225441A (en) * | 1987-06-18 | 1993-07-06 | Block Drug Company, Inc. | Treatment of periodontal disease |
US5260445A (en) | 1987-09-04 | 1993-11-09 | Beecham Group P.L.C. | 2,4-thiazolidinediones |
US5194443A (en) | 1987-09-04 | 1993-03-16 | Beecham Group P.L.C. | Compounds |
US5232925A (en) | 1987-09-04 | 1993-08-03 | Beecham Group P.L.C. | Compounds |
ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
US5223522A (en) | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
WO1989008650A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
US5120754A (en) | 1988-03-08 | 1992-06-09 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
MX15171A (es) | 1988-03-08 | 1993-05-01 | Pfizer | Derivados de tiazolidinodiona hipoglicemicos |
JP2524217B2 (ja) * | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
JPH01279827A (ja) * | 1988-05-02 | 1989-11-10 | Taiyo Fishery Co Ltd | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
US5208250A (en) | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
US4897405A (en) | 1989-04-21 | 1990-01-30 | American Home Products Corporation | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
GB8919434D0 (en) | 1989-08-25 | 1989-10-11 | Beecham Group Plc | Novel compounds |
WO1991007107A1 (en) | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
US5143928A (en) | 1990-03-27 | 1992-09-01 | Warner-Lambert Company | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents |
WO1991017151A1 (en) | 1990-04-27 | 1991-11-14 | Orion-Yhtymä Oy | New pharmacologically active catechol derivatives |
GB9017218D0 (en) | 1990-08-06 | 1990-09-19 | Beecham Group Plc | Novel compounds |
US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
US5143929A (en) | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents |
JPH0543456A (ja) * | 1991-08-13 | 1993-02-23 | Sagami Chem Res Center | 血小板活性化因子産生阻害剤 |
US5714470A (en) | 1991-08-22 | 1998-02-03 | Merrell Pharmaceuticals, Inc. | Orally-active elastase inhibitors |
US5270319A (en) | 1991-09-09 | 1993-12-14 | Warner-Lambert Company | 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents |
JP3213760B2 (ja) * | 1991-10-24 | 2001-10-02 | マルハ株式会社 | 痴呆疾患の治療または予防の為の組成物と、それを処方物にした抗痴呆薬 |
EP0637957B1 (de) * | 1992-04-28 | 1997-07-23 | Fresenius AG | Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen |
US5326770A (en) * | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
GB2269992A (en) | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
EP0587377A3 (en) * | 1992-09-10 | 1994-09-21 | Lilly Co Eli | Thiazolidinone derivatives as hypoglycemic agents and for treating alzheimer's disease |
US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
JPH08511533A (ja) * | 1993-06-09 | 1996-12-03 | マーテック・バイオサイエンスィズ・コーポレーション | 神経学的障害の治療に有用な方法および医薬用組成物 |
US5457109A (en) | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
JPH07291867A (ja) * | 1994-04-28 | 1995-11-07 | Sagami Chem Res Center | 神経成長因子産生促進剤 |
JPH07143862A (ja) * | 1994-05-06 | 1995-06-06 | Maruha Corp | 脳機能改善効果を有する機能性食品。 |
JPH07309773A (ja) * | 1994-05-16 | 1995-11-28 | Sagami Chem Res Center | アセチルコリン放出促進剤 |
US5607967A (en) * | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
JPH08143454A (ja) * | 1994-11-17 | 1996-06-04 | Kanagawa Kagaku Kenkyusho:Kk | 神経成長因子産生増強剤 |
US5824692A (en) | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US6022897A (en) | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
AU725998B2 (en) * | 1995-09-18 | 2000-10-26 | Eisai R&D Management Co., Ltd. | Treating NIDDM with RXR agonists |
US5618835A (en) | 1996-02-01 | 1997-04-08 | The Procter & Gamble Company | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
IN182496B (xx) | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
JP2001507706A (ja) * | 1996-12-31 | 2001-06-12 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | Ppar―ガンマ活性化物質を使用する新生細胞増殖の結果である疾病状態の処置及びこの処置に有用な組成物 |
US5814647A (en) * | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
DE69838789T2 (de) * | 1997-03-12 | 2008-10-30 | Suzanne Cambridge de la Monte | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
EP1047423B1 (en) | 1997-11-19 | 2006-05-10 | Takeda Pharmaceutical Company Limited | Novel apoptosis inhibitors |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
JP2011030253A (ja) * | 2010-09-17 | 2011-02-10 | Maspro Denkoh Corp | 送信装置 |
-
1998
- 1998-11-27 US US09/200,700 patent/US6191154B1/en not_active Expired - Lifetime
-
1999
- 1999-11-24 CA CA002352494A patent/CA2352494C/en not_active Expired - Fee Related
- 1999-11-24 WO PCT/US1999/027987 patent/WO2000032190A1/en active Application Filing
- 1999-11-24 AT AT99963985T patent/ATE478669T1/de not_active IP Right Cessation
- 1999-11-24 AU AU20312/00A patent/AU765528C/en not_active Ceased
- 1999-11-24 DE DE69942702T patent/DE69942702D1/de not_active Expired - Lifetime
- 1999-11-24 KR KR10-2001-7006618A patent/KR100520856B1/ko not_active IP Right Cessation
- 1999-11-24 EP EP99963985A patent/EP1133294B1/en not_active Expired - Lifetime
- 1999-11-24 IL IL14331399A patent/IL143313A0/xx not_active IP Right Cessation
- 1999-11-24 JP JP2000584885A patent/JP4932991B2/ja not_active Expired - Fee Related
-
2005
- 2005-06-13 KR KR10-2005-7010803A patent/KR100521829B1/ko not_active IP Right Cessation
-
2011
- 2011-02-15 JP JP2011030253A patent/JP5730055B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-23 JP JP2012037726A patent/JP2012140443A/ja active Pending
-
2013
- 2013-11-25 JP JP2013243397A patent/JP5745012B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69942702D1 (de) | 2010-10-07 |
KR20050067240A (ko) | 2005-06-30 |
WO2000032190A1 (en) | 2000-06-08 |
JP5730055B2 (ja) | 2015-06-03 |
KR100521829B1 (en) | 2005-10-17 |
AU765528B2 (en) | 2003-09-18 |
US6191154B1 (en) | 2001-02-20 |
EP1133294A1 (en) | 2001-09-19 |
ATE478669T1 (de) | 2010-09-15 |
JP2012140443A (ja) | 2012-07-26 |
JP2014058546A (ja) | 2014-04-03 |
JP2011093941A (ja) | 2011-05-12 |
CA2352494A1 (en) | 2000-06-08 |
EP1133294A4 (en) | 2003-01-08 |
EP1133294B1 (en) | 2010-08-25 |
KR100520856B1 (ko) | 2005-10-17 |
AU765528C (en) | 2004-09-30 |
JP4932991B2 (ja) | 2012-05-16 |
AU2031200A (en) | 2000-06-19 |
KR20010101085A (ko) | 2001-11-14 |
JP2002536294A (ja) | 2002-10-29 |
CA2352494C (en) | 2009-11-17 |
JP5745012B2 (ja) | 2015-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100521829B1 (en) | Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases | |
IL267381A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
BG105588A (en) | Anthranilic acide amides and the use thereof as medicaments | |
ATE492279T1 (de) | Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen | |
DE69726724D1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
IL132293A0 (en) | Use of lactoferin in the treatment of allergen induced disorders | |
TW264480B (xx) | ||
ATE229806T1 (de) | Wirkstoff zur behandlung neurodegenerativer störungen | |
IL153147A0 (en) | Phospholipid derivatives of valporic acid and mixtures thereof | |
EP1032556A4 (en) | PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION | |
IL141325A0 (en) | Tan-1057 derivatives | |
EP0383171A3 (en) | 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders | |
WO2001057042A3 (de) | 4-pyridyl- und 2,4-pyrimidinyl-substituierte pyrrolderivate und ihre anwendung in der pharmazie | |
ZA9010080B (en) | 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants | |
HU9201799D0 (en) | New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments | |
DE60023139D1 (de) | Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen | |
TWI245756B (en) | Improved process for the preparation of 1,3-substituted indenes | |
WO2002076437A3 (en) | Methods for treating neurodegenerative diseases including alzheimer's | |
ATE384133T1 (de) | Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen | |
UA33498A (uk) | Спосіб лікування терапевтично резистентних форм шизофренії | |
TJ387B (en) | The present invention relates to medicine and can be used for treatment of inflammatory process of aleather. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |